Cardioxyl

Nitroxyl Technology

Cardioxyl has developed industry leading expertise in nitroxyl (HNO) chemistry and biology, and is employing its nitroxyl chemistry platform to discover and develop novel, proprietary therapeutics targeting cardiovascular disease.
Read More

CXL-1020

Cardioxyl's lead clinical candidate, CXL-1020, is in development for acute decompensated heart failure. The compound is currently under investigation in a multi-center Phase I/IIa clinical trial.
Read More